EtG and ethyl sulfate: EtS) was employed to analyze 193 fetal liver and 48 placenta (n = 47 paired) samples from electively terminated pregnancies. Results EtG, EtS, and nicotine markers' limits of detection were 0.7-20 ng/g in fetal samples. Ninety-eight fetal liver and 23 placenta samples were EtG/EtS-positive, while 137 liver and 25 placenta samples were positive for tobacco exposure. When both alcohol markers were present in samples, EtG/EtS ratios were 1.6-11.1 in 17 livers and 2.5-31.1 in 10 placentas. Median (range) summed tobacco marker concentrations were 422 (1.0-2776) and 154 (1.6-1621) ng/g in livers and placentas, respectively. Median EtG and nicotine marker concentrations were higher in liver than placenta in paired samples. Strong evidence of exposure occurred in 11 and 22 pairs, respectively, when both samples were positive for alcohol and/or tobacco markers. Conclusions These paired fetal liver and placenta alcohol and tobacco data provided a unique means for examining the effects of in utero exposure, a critical first step in selecting fetal samples for proteomic and RNA sequencing studies that could provide mechanisms for adverse developmental outcomes.
Introduction
Tobacco and alcohol use during pregnancy is serious public health concerns, resulting in adverse obstetrical and neonatal outcomes including miscarriage, preeclampsia, low birth weight, preterm delivery, fetal growth restriction, decreased head circumference, placenta abruption, and facial abnormalities [1] [2] [3] [4] . Fetal alcohol spectrum disorders (FASD) encompass growth retardation, cognitive impairments, and craniofacial dysmorphology associated with prenatal alcohol exposure [5, 6] . Prenatal tobacco exposure also can have a profound impact on infant brain structure and function, infant irritability, and risk for child behavioral and attention disorders [7, 8] . Despite these documented health risks, in the 2015 US National Survey of Drug Use and Health (NSDUH), 13 .9% of pregnant respondents reported current tobacco use and 9.3% current alcohol use [9] .
Identifying prenatal alcohol and tobacco exposure is often achieved through meconium drug quantification and/ or maternal self-reported drug use during pregnancy. Meconium is a good matrix for in utero drug exposure assessment in pregnancies carried to term. Although meconium formation begins as early as 13 weeks, other methods must assess earlier exposure. In this study, we examined whether analysis of fetal liver and placenta from electively terminated pregnancies could determine exposure patterns during the second trimester.
In adults, nicotine is oxidized to cotinine and trans-3′-hydroxycotinine (OHCOT) primarily by CYP2A13 and CYP2A6 [10] , with additional phase II conjugation to nicotine-N-glucuronide (Nic-G), cotinine-N-glucuronide (Cot-G), and OHCOT-O-glucuronide (OHCOT-G) [10] . Nicotine and these five metabolites account for 73-96% of the nicotine dose excreted in adult smokers' urine [10] . Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are chemical markers indicating ethanol ingestion with longer detection times than ethanol. UDP-glucuronosyltransferase catalyzes ethanol conjugation with glucuronic acid to form EtG [11] , while sulfotransferases conjugate ethanol and activated sulfate to form EtS [12] . Fetal liver and placental EtG is likely of maternal origin as EtG readily crosses the placenta and fetal glucuronidation capacity is limited [13, 14] . Little is known about placental EtS transfer; however, fetal liver and placental EtS concentrations may result from maternal and/ or fetal contributions, as variable yet significant fetal sulfotransferase activity was observed [15, 16] . Fetal liver and placental EtG and EtS levels were investigated previously in a small cohort with few positives [17] , while there are no available data on human fetal liver nicotine and its metabolites' concentrations.
Adult health is partly programmed during fetal development [18] [19] [20] [21] . Gestational exposure to tobacco, alcohol, and other drugs alters normal hormone regulation early in fetal development [22, 23] . Mechanisms through which fetal drug exposures result in reduced adult health are poorly understood. We present a validated analytical method for quantifying EtG/EtS and nicotine markers in fetal liver and placenta samples and describe how this method assessed in utero alcohol and tobacco exposure in fetuses from electively terminated pregnancies. The goal was to select the most appropriate fetal samples to conduct fetal endocrine disruption and DNA/RNA damage assessments.
Materials and methods

Tissue samples
The drug-and alcohol-negative matrix for human fetal liver analyses was a frozen calf liver. Human placentas from healthy pregnancies were donated by volunteers and the Johns Hopkins Bayview Medical Center Pathology Department. Blank matrices were confirmed negative at our limits of quantification (LOQs) prior to calibrator and quality control (QC) preparation. Samples (193 fetal livers and 48 placentas including 47 paired samples) obtained from women who voluntarily terminated their pregnancies were analyzed. Fetus collection in Aberdeen was approved by the NHS Grampian Research Ethics Committees (REC 04/ S0802/21). Women seeking elective terminations of pregnancy were recruited with full written, informed consent by nurses working independently of the study at Aberdeen Pregnancy Counseling Service. Maternal data, medications used, and self-reported number of cigarettes smoked per day were recorded. Only fetuses from normally progressing pregnancies (determined by ultrasound scan), from women > 16 years old and between 8-20 weeks of gestation, were collected following termination as detailed previously [24] . Fetuses were transported to the laboratory within 30 min of delivery, weighed, crown-rump length recorded, and sexed. Collection of human fetal liver and placenta pairs occurred at the University of Newcastle upon Tyne (England) through the Human Developmental Biology Resource at the Institute of Human Genetics under an institutional review board-approved study. ) ; LCMS grade methanol, ammonium acetate, formic acid, HPLC grade acetonitrile, dichloromethane, isopropanol, ACS grade hydrochloric acid, and ammonium hydroxide were purchased from Fisher Scientific (Fair Lawn, NJ, USA); fritted filters (10 µm, 15 mL) were purchased from United Chemical Technologies Inc. (Bristol, PA, USA); Isolute-supported liquid extraction (SLE) columns (1 mg/6 mL) and Evolute-AX anion exchange solid-phase extraction (SPE) cartridges (100 mg/3 mL) were purchased from Biotage (Charlotte, NC, USA).
Reagents
S(−)-
Instrumentation
Tobacco and alcohol markers were quantified on a SCIEX 5500 Qtrap ® mass spectrometer with a TurboV electrospray ionization (ESI) source (SCIEX, Foster City, CA, USA), connected to a Shimadzu UFLCXR system with two LC-20ADXR pumps, a CTO-20 AC column oven, and a SIL-20ACXR autosampler (Shimadzu Corporation, Columbia, MD, USA). Data were acquired and processed with Analyst 1.5.1 (SCIEX). A Mini-BeadBeater-8 (BioSpec Products, Bartlesville, OK, USA) was utilized to pulverized tissue. A CEREX-48 positive-pressure manifold was utilized for SPE (SPEware Corporation, Baldwin Park, CA, USA). Evaporation under nitrogen was conducted in a TurboVap LV evaporator (Zymark, Hopkinton, MA, USA).
Standard solution preparation
Individual methanolic standard solutions were diluted to 100 mg/L in methanol. Powdered standards were reconstituted in the manufacturer's recommended solvent and diluted to 100 mg/L in methanol, except for OHCOT, which was maintained at 1 g/L. Methanolic dilutions yielded mixed working calibrator solutions of 0.01, 0.02, 0.05, 0.1, 0.25, 0.5, 1.5, and 3 mg/L for cotinine, and 2.5, 5, 10, and 20 times more concentrated for Nic-G, OHCOT; nicotine, EtS, Cot-G; OHCOT-G; and EtG, respectively. QC solutions were prepared from different stocks than calibrators. Low, medium, and high QCs were prepared across the linear dynamic range for each analyte. A mixed working internal standard methanolic stock was prepared at 0.1 (cotinine- 
Procedures
Blank liver or placenta (0.25 g) was fortified with 25 µL calibrator or QC solution, or 25 µL methanol for authentic samples, and 25 µL internal standard solution was added. Six to eight 3.2-mm chrome-steel beads were added to each sample, followed by 0.95 mL of 0.01% formic acid in methanol and pulverized for 2 s. The methanol was filtered and collected in polypropylene tubes. The original samples were rinsed with an additional 1 mL 0.01% formic acid in methanol, vigorously vortexed for 1 min, and filtered into the same tubes. Two 450-µL aliquots were transferred to separate tubes for SLE of nicotine and its metabolites and for anion-exchange SPE of EtG and EtS.
For nicotine and metabolite extraction, 525 µL of 0.25% ammonium hydroxide in methanol was added to the nicotine aliquot yielding pH > 10. Samples were vortexed and poured onto 1-mL SLE beds. After 5 min of equilibration, analytes were eluted with 2 × 2.5 mL of dichloromethane/isopropanol (95:5, v/v) into glass centrifuge tubes. Positive pressure was gradually applied up to 2.4 L/min to complete elution. A 50-µL volume of 1% HCl in methanol was added to the eluents before evaporation under nitrogen at 35 °C. Reconstitution occurred in 200 µL of 10 mM ammonium acetate in water with 5 µL of methanol added to aid pellet formation. Samples were vortexed and centrifuged at 1800 g at 4 °C for 5 min. A 150-µL volume was transferred to a microcentrifuge tube and centrifuged at 20,800 g for 5 min at 4 °C. A 125-µL volume was transferred to autosampler vials and 5 µL was injected. For EtG and EtS extraction, 2 mL of acetonitrile and 10 µL of 236 mM ammonium hydroxide were added to the 450 µL of tissue supernatant, and the SPE followed our published meconium assay for these markers [25] .
Liquid chromatography-tandem mass spectrometry
Nicotine and its metabolites were chromatographically separated on a Poroshell 120 EC-C8 column (150 × 2.1-mm i.d., 2.7-µm particle size), fitted with a matching guard column (Agilent Technologies, Santa Clara, CA, USA) similarly to a previous publication [26] . Mobile phases A and B were 10 mM ammonium acetate in water and methanol, respectively. At 0.3 mL/min flow, the gradient started at 0% B, increased to 60% B over 6 min, increased to 100% B in 0.1 min, held at 100% B for 2.4 min, decreased to 0% B in 0.1 min, and held for 2.9 min; total run time was 11.5 min. Liquid chromatograph (LC) eluent was diverted to waste for the first min and the final 5.5 min.
Mass spectrometric data for nicotine and metabolites were acquired via positive ESI. Compound-specific tandem mass spectrometry (MS/MS) parameters were optimized by infusing 10 µg/L of reference solutions at 10 µL/min dissolved in A/B (50:50, v/v) mobile phase (Table S1 ). Optimized source parameters were gas 1 at 60 psi, gas 2 at 40 psi, curtain gas at 45 psi, source temperature of 700 °C, and ion spray voltage of 5500 V. Three periods were utilized to acquire multiple reaction monitoring (MRM) mode data with period 1 (2. LC and MS parameters for EtG and EtS were adapted from our previously published meconium method [25] . However, the quantifying EtG transition, m/z 221 > 75, was replaced by m/z 221 > 85, due to matrix interferences at low concentrations (Table S1 ).
Validation
Sensitivity, linearity, specificity, accuracy, imprecision, extraction efficiency, matrix effect, dilution integrity, carryover, and stability were evaluated according to Scientific Working Group for Forensic Toxicology (SWGTOX) guidelines [27] as summarized in Table S2 .
Results
This method is the first to offer simultaneous extraction of EtG, EtS, nicotine, cotinine, OHCOT, and three prominent nicotine glucuronide metabolites from a human fetal liver or placenta sample. Although initial tissue extraction was simultaneous, marked physiochemical differences between acidic EtG and EtS and basic nicotine and metabolites required different SPE and LC approaches.
Limits of detection (LODs), LOQs, linear ranges, and calibration curves for both matrices are presented in Table 1 . Accuracy and imprecision results for liver and placenta are presented in Table 2 . Extraction recoveries and matrix effects for liver and placenta are given in Table 3 . Stability results for all conditions and all samples are summarized in Table 4 . All validation experiments met acceptability criteria (Table S2 ).
The validated methods were used for the analysis of 193 fetal liver and 48 placenta (47 paired) samples. Summarized concentration data for all analytes and matrices are found in Table 5 . When both alcohol markers were present in a sample (17 livers and 10 placenta samples), an EtG/EtS ratio was calculated and ranged from 1.6 to 11.1 in liver and 2.5-31.1 in placenta. The six tobacco marker concentrations in each individual sample were summed. Median (range) summation concentrations were 422 (1.0-2776) and 154 (1.6-1621) ng/g in liver and placenta, respectively.
We identified in utero alcohol and tobacco exposures based on EtG/EtS and nicotine marker concentrations in liver and placenta. Currently, there are not sufficient preexisting fetal data in the literature to guide interpretation. Our criteria for determining evidence of alcohol and tobacco exposure are described in Table 6 , based on presence of and concentrations of multiple analytes. For each matrix, numbers of samples in each predicted exposure category are also tabulated. Results from this study are utilized for selecting fetuses for later DNA and RNA analyses that will examine exposure and possible damage at the genomic level.
When both alcohol markers were detected together, EtG concentrations were 27.0-2050 ng/g and 34.3-1168 ng/g, and EtS concentrations were 7.3-423 ng/g and 7.9-214 ng/g in 17 fetal livers and 10 placentas, respectively. Only one fetal liver had detectable EtG (31.9 ng/g) without EtS with Table 1 Linearity, limit of detection (LOD), and limit of quantification (LOQ) results
SD standard deviation, OHCOT trans-3′-hydroxycotinine, R
2 coefficient of determination /48 placenta (6.9-35.6 ng/g) samples. Median EtG concentrations were higher in liver than placenta (Table 5) . Of the 11 paired samples indicating strong evidence of recent alcohol exposure, three pairs contained both markers in both matrices, while three pairs were negative in liver but positive for EtG and EtS in placenta. Overall, 95/193 fetal liver and 25/48 placenta samples, including 21 paired samples, were negative for EtG and EtS (Table 6) . One or more nicotine markers were detected in 137/193 liver and 25/48 placenta samples. Median nicotine and metabolite concentrations were higher in liver than in placenta, including median concentration sums (Table 5) . Low tobacco marker concentrations or presence of few analytes were difficult to interpret and were classified as weak or moderate evidence of recent exposure, but did not preclude previous maternal use if there was a period of abstinence prior to pregnancy termination. Summed nicotine marker concentrations weakly indicative of recent tobacco exposure were 1.0-13.0 ng/g and 1.6-10.8 ng/g in fetal liver and placenta, respectively, while moderate evidence encompassed summed concentrations of 8.3-421 ng/g and 43.7-154 ng/g in fetal liver and placenta, respectively. When strong evidence of tobacco exposure was predicted, summed concentrations were 290-2776 ng/g and 148-1621 ng/g in fetal liver and placenta, respectively (Table 5 ). Of the paired samples, six indicated strong evidence of both alcohol and tobacco exposure. No tobacco analytes were detected above the LOQ in 56/193 fetal livers and 23/48 placentas, including 20 paired samples (Table 6) .
Discussion
This novel, comprehensive method was fully validated according to SWGTOX guidelines [27] for EtG, EtS, nicotine, and phase I and phase II metabolites in fetal liver or placenta samples. The methodology was successfully applied to the analysis of 193 fetal liver and 48 placenta samples from electively terminated pregnancies for the determination of in utero exposure to alcohol and tobacco. Our investigation is only the second to look at fetal liver and placental EtG and EtS. A previous study by Morini et al. [17] tested 35 matched liver-placenta pairs from women who terminated their pregnancy at week 12. In this previous study, four fetal livers were EtG-positive (33-391 ng/g) with three also positive for EtS (15-51 ng/g). In placenta, four were EtG-(122-1307 ng/g) and EtS-positive (10-126 ng/g) and were paired with the four fetal livers with detectable EtG. Two additional placenta samples were positive only for EtS (29 and 175 ng/g). EtG/EtS ratios in the three dualpositive liver samples were 3.9, 5.3, and 7.3; while EtG/EtS ratios in the four dual-positive placentas were 12.7, 12.7, 4.8, and 10.4. EtG and EtS were always higher in placenta compared to those in liver [17] . Our EtS LOQ is the same as that of Morini et al. (5 ng/g) [17] , but our EtG LOQ was 20 ng/g. We fully homogenized the 250 mg of liver by beadbeating, enabling a more efficient and reproducible release of drugs as compared to an acetonitrile wash reported by them, but produced additional matrix effects, requiring us to raise our LOQ. However, our LOQ was below the concentrations in all samples identified and reported by them.
In order to select samples for further testing, we examined alcohol and tobacco markers in fetal, infant, and adult studies. EtG readily crosses the placenta [20] ; therefore, fetal liver EtG is likely to be primarily of maternal origin, as fetal glucuronidation capacity is limited [13] . No placental diffusion EtS studies exist. However, fetal liver sulfotransferases showed variable yet significant activities [15] . It is possible that the fetal liver EtS is of fetal origin, or of both fetal and maternal origin.
When considering adult alcohol markers, if EtG and EtS are present, there is a strong indication of alcohol ingestion [28] . EtG and EtS are only produced by antemortem drinking, enabling differentiation of postmortem ethanol formation from antemortem drinking. EtG was reported to occasionally degrade in postmortem samples [28, 29] , suggesting the superiority of EtS analysis. In addition, EtS is not formed in the presence of putrefaction or with lack of preservatives [28, 30] . For our fetal samples, the presence of EtS or EtG only, as well as that of both compounds, can be considered alcohol-exposed.
In meconium, we previously reported that cotinine, nicotine, or OHCOT concentrations ≥ 10 ng/g suggested active maternal tobacco exposure during pregnancy [31] , although subsequent work by our group found lower cutoffs, equivalent to analytical LOQs (1 ng/g cotinine, 2.5 ng/g nicotine, and 5 ng/g OHCOT), and better identified active maternal smoking [3] . This suggests that detecting any marker in meconium indicates maternal smoking during pregnancy, and environmental or passive exposure would produce undetectable tobacco marker concentrations in meconium. In serum, cotinine ≤ 3 ng/mL differentiated passive from active maternal exposure [10, 31] . In support of our previous 10-ng/g cutoff, Braun et al. [32] showed that in infants of tobacco-smoking mothers with a mean serum cotinine > 3 ng/mL, the lower limit of the 95% confidence interval for meconium cotinine was 10 ng/g. Additionally, among these infants with exposure to maternal active tobacco smoking, multiple meconium tobacco markers were detected [31] . For our fetal samples, presence of multiple markers, especially above the median, was considered the criteria for being considered tobacco-exposed. To our knowledge, these are the first fetal liver tobacco marker concentrations, although there are other placenta and fetal human brain concentration data. The transfer rate for nicotine across the placenta was about 90% [33] . In 12th week-terminated pregnancies, evidence of fetal tobacco exposure was observed, with placenta median (range) cotinine and nicotine concentrations of 80 ng/g and 61 (33-120) ng/g, respectively [34] . In a single human postmortem fetal brain sample, 40 ng/g cotinine, 65 ng/g OHCOT, and no nicotine were detected [35] , although the timing of tobacco exposure was unavailable. In adult postmortem liver, cotinine was always higher (4-25 times) than nicotine and both analytes were detected at higher concentrations than in blood; cotinine and nicotine concentrations in adult liver were 260-1586 ng/g and 14-325 ng/g, respectively [36] .
We predicted alcohol and tobacco exposure based on analyte presence and their concentrations, although there are few data to guide interpretation. It is important to publish quantitative data for future investigations. Molecular analyses in prenatal alcohol and tobacco-exposed fetuses may eventually suggest mechanisms for adverse fetal outcomes and perhaps correlations between fetal liver or placenta concentrations and outcomes. Relevantly, a balanced population of the 80 fetal livers and the 145 Aberdeen fetal livers that we report here is currently being analyzed by shotgun proteomics and RNA sequencing. No recent alcohol exposure was demonstrated by absence of EtG and EtS, as absence of these markers may only indicate maternal abstinence for a few days prior to termination. It is possible that these samples could provide a wider window of alcohol or tobacco detection, but we have no data on timing or magnitude of exposure. The fetal liver EtG detection window following acute or chronic maternal alcohol consumption is unknown, although EtG and EtS are detected in adult urine for 40-130 h after the end of drinking in most cases [37, 38] .
Fetuses exhibiting strong evidence of recent alcohol exposure were selected primarily from samples positive for both EtG and EtS (n = 17 for liver, n = 10 for placenta), with additional two placentas identified when EtG concentration met or exceeded the median concentration. Moderate evidence of recent alcohol exposure identified 45 liver and 4 placenta samples with EtS detected ≥ median concentration despite no detectable EtG. Given potential EtG instability and a higher EtG LOQ, EtS-only-positive cases could indicate exposure. In addition, differential metabolic pathway rates in mothers or fetuses could result in more EtS than EtG as EtS is stable [28] , and there are no published cases of artificial EtS formation. However, in adults, urine EtS detection could occur after extreme non-traditional drinking behaviors, including nonalcoholic beer [39] , sauerkraut [39] , ripened bananas [39] , grape juice [39] , and non-alcoholic wine [29] . In the present study, three placentas were EtG-and EtS-positive, although paired liver samples were negative. Additionally, three liver samples were positive for EtS-only (8.6, 9.9, and 17.0 ng/g) with no analytes detected in placenta, while nine EtS-only placenta (6.9-35.6 ng/g) samples had paired liver samples negative for both alcohol markers. Therefore, alcohol exposure was suggested in this study, but cannot be definitively determined.
No recent tobacco exposure was identified in fetal liver and placenta samples that were negative for all six tobacco markers. Tobacco marker absence may indicate recent maternal abstinence but not necessarily throughout pregnancy. Detection windows for tobacco markers in fetal liver and placenta are unknown. In cases where only a few markers were detected, interpretation was difficult and low concentrations could possibly be attributed to minimal maternal smoking, abstinence for a few days prior to termination, or passive maternal tobacco smoke exposure. Large population sampling studies showed positive, but low mean serum cotinine concentrations among self-reported nonsmokers and passively exposed individuals [10] . For this reason, samples positive for 5/6 or 6/6 analytes with high summed concentrations were considered to exhibit strong evidence of recent tobacco exposure, especially due to the presence of phase I and phase II nicotine metabolites.
Conclusions
While timing of gestational alcohol or tobacco use is unknown, we were able to identify multiple, specific alcohol and tobacco markers for selecting samples for proteomic and RNA sequencing studies. Our validated analytical method successfully quantified alcohol (EtG and EtS) and tobacco markers (nicotine and phase I and phase II metabolites) and sought to predict alcohol and tobacco exposure. After consulting the literature for fetal studies and examining analyte concentrations in other matrices, we stratified our fetal liver and placenta data to categorize strength of evidence of recent maternal alcohol or tobacco consumption, exposing preterm fetuses to potentially harmful chemicals at a young gestational age. For the first time, a large cohort of paired, exposed fetal liver and placenta samples were analyzed. Publishing these data is crucial to inform future research, as this is the first comprehensive analysis of paired fetal liver and placenta samples for evidence of in utero alcohol and tobacco exposure.
